Cognition Therapeutics Inc Cash Flow-to-Debt Ratio
Cognition Therapeutics Inc cash flow-to-debt ratio. Cognition Therapeutics Inc (CGTX) has a Cash Flow-to-Debt Ratio of -0.82x as of September 2025, meaning its operating cash flow of $-5.65 Million could theoretically repay -1% of its total liabilities ($6.87 Million) in one year. Check earnings quality score of Cognition Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cognition Therapeutics Inc (2019–2024)
Cash flow-to-debt ratio of Cognition Therapeutics Inc from 2019 to 2024. Historical debt coverage capacity for Cognition Therapeutics Inc across 6 annual periods. Check CGTX capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Cognition Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2024)
Cognition Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Cognition Therapeutics Inc. For the full cash flow conversion analysis, see CGTX cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.48x | $-28.47 Million | $11.48 Million | ▼ -65.5% |
| 2023 | -1.50x | $-16.02 Million | $10.69 Million | ▲ +17.7% |
| 2022 | -1.82x | $-18.53 Million | $10.18 Million | ▼ -294.4% |
| 2021 | -0.46x | $-3.63 Million | $7.86 Million | ▼ -912.8% |
| 2020 | -0.05x | $-3.43 Million | $75.30 Million | ▲ +3.1% |
| 2019 | -0.05x | $-3.10 Million | $65.88 Million | — |